United States: The Long-Awaited 340B Drug Pricing Program Omnibus Guidance: Part IV

Last Updated: October 14 2015
Article by Kathleen A. Reed

Duplicate Discounting, Recordkeeping, Audit and Repayment

This is the fourth and final in a series of updates addressing the 340B Drug Pricing Program Omnibus Guidance published by the Health Resources and Services Administration (HRSA) on August 28, 2015 (Guidance). The proposed Guidance clarifies various aspects of covered entity and drug manufacturer compliance with Section 340B of the Public Health Service Act (PHSA), topics that are currently addressed in a number of HRSA guidance documents published in the Federal Register dating back to 1992. This update addresses issues of duplicate discounting, recordkeeping, audit and repayment matters under the 340B Drug Pricing Program (340B Program).

Duplicate Discounting

In addition to the discounting required under the 340B Program, the Social Security Act also requires drug manufacturers to provide a rebate to a state for a covered outpatient drug provided to a Medicaid fee-for-service (FFS) or Medicaid managed care organization (MCO) patient. In order to prevent duplicate discounting under both the 340B Program and the Medicaid rebate, HHS has created the Medicaid Exclusion File. Upon enrolling in the 340B Program, a Covered Entity must notify HHS as to whether it will purchase and dispense 340B Covered Drugs to its Medicaid patients ("carve in") or will not use 340B discounted drugs to dispense to its Medicaid patients ("carve out"). A Covered Entity that opts to carve in will have its NPI and/or Medicaid billing number listed in the Medicaid Exclusion File, providing states with a mechanism for determining which outpatient drug dispensing events are eligible for a Medicaid rebate, and which are not. A Covered Entity may make different carve in/carve out status decisions with regard to its FFS Medicaid patients than it makes for its MCO Medicaid patients. Further, a Covered Entity may also make different carve in/carve out decisions by Covered Entity site and by MCO. However, the Covered Entity must provide HHS with specific information identifying each site and MCO for inclusion in the Medicaid Exclusion File. A Covered Entity may notify HHS of a change in its carve in/carve out status at any time, but the decision becomes effective only on a quarterly basis.

Recordkeeping

The PHSA requires Covered Entities to allow HHS and certain manufacturers to audit the Covered Entity's records that pertain to compliance with 340B Program requirements. Because maintenance of auditable records is a condition of eligibility for the 340B Program, failure to maintain such records can result in termination of the Covered Entity from the 340B Program. However, the Guidance states that HHS will use discretion when terminating for record keeping failures, and will not necessarily terminate if the Covered Entity's non-compliance is not systemic. For example, a Covered Entity that generally keeps auditable records but is unable to produce records regarding a specific instance of dispensing will not be terminated from the 340B Program, but would be presumed to have diverted the drug for which there is no record, and would be liable for repayment. In addition to termination, a systemic failure of recordkeeping could also subject a Covered Entity to repayment for all time periods during which auditable records were not maintained. HHS will provide a Covered Entity with notice and an opportunity for a hearing prior to termination for ineligibility due to lack of recordkeeping. A dis-enrolled Covered Entity is permitted to re-enroll at the next regular enrollment period at which it can demonstrate compliance with the auditable recordkeeping requirement.

Interestingly, the Guidance does not contain specific requirements for the form or content of the required auditable records. We recommend that a Covered Entity insure that its records can demonstrate compliance with all of the requirements applicable to the Covered Entity set forth in the Guidance. The Guidance also requires that records be maintained with regard to all child sites and Contract Pharmacies, and proposes that they be maintained for not less than five years. For terminated Covered Entities, records must be maintained for five years after the date of termination.

Audits

Covered Entity Audits

While the Guidance recommends that Covered Entities undertake regular audits of their compliance with 340B Program requirements, it does not dictate who must audit (internal or external), how often audits must occur, or the content of a such audits, except when the audit pertains to a Contract Pharmacy. In contrast to past HRSA guidelines, the Guidance now specifically recommends that Covered Entities conduct annual audits of their Contract Pharmacies undertaken by independent auditors. Further, as a separate compliance mechanism, the Covered Entity should perform comparisons of the 340B drugs dispensed by a Contract Pharmacy against the Covered Entity's 340B prescribing records on a quarterly basis. The Guidance instructs Covered Entities to correct any instances of duplicate discounts or diversion discovered during annual audits or quarterly reviews, and report the corrective action to HHS.

HHS Audits

The PHSA also gives HHS authority to audit Covered Entities and drug manufacturers to check for compliance with 340B Program requirements (this update will focus only on HHS audits of Covered Entities, not manufacturers). A Covered Entity that does not give HHS access to all records pertaining to its compliance, including records of child sites and Contract Pharmacies, may be terminated from the 340B Program. HHS is limited to conducting only one audit per Covered Entity at any given time, and is obligated to minimize disruptions to the Covered Entity while conducting the audit. HHS may audit for compliance with 340B Program requirements, satisfaction of enrollment and eligibility requirements, as well as the accuracy of the information in the 340B data base, and may perform its audits on- or off-site.

New under the Guidance, HHS is proposing a notice and hearing process that will give Covered Entities the opportunity to respond to adverse HHS audit findings, "other instances of noncompliance" and proposed loss of 340B Program eligibility. The notice and hearing process will be conducted "on the record" based on documents timely submitted by the Covered Entity in response to a notice from HHS detailing the alleged noncompliance. A Covered Entity's failure to respond to an HHS notice within 30 days, or to obtain an extension, will constitute the Covered Entity's agreement with the noncompliance alleged in the HHS notice. HHS will review the Covered Entity's timely submissions and make a final determination that may require a corrective action plan by the Covered Entity or may result in termination from the 340B Program. The Guidance indicates that HHS will work with Covered Entities to determine a timeline for submitting a corrective action plan. HHS characterizes the corrective action plan and all documentation of its implementation as auditable records that must be maintained by the Covered Entity as such.

Manufacturer Audits

The PHSA authorizes a drug manufacturer to audit a Covered Entity's compliance with statutory prohibitions against duplicate discounts and diversion of 340B Covered Drugs. A manufacturer is not permitted to audit a Covered Entity's compliance with 340B Program eligibility requirements. Before it may conduct an audit, a manufacturer must establish, to HHS's satisfaction, that a "reasonable cause" exists to conclude that a Covered Entity has violated the diversion or duplicate discount prohibitions. The Guidance provides examples of what facts or evidence may constitute reasonable cause, which may include a Covered Entity's failure to respond to a manufacturer's questions regarding diversion and duplicate discounts. Additionally, a manufacturer must develop an audit work plan with HHS to insure that its audit is limited to permitted issues. The Guidance explains the standards which apply to manufacturer audits, including use of an independent certified accounting firm to perform the audit in accordance with government auditing standards, and limiting the duration of an audit to one year. The Covered Entity is required, under PHSA, to provide records necessary to conduct the audit as a condition of its eligibility for the 340B Program. At the end of the audit, the independent auditor submits a final audit report to HHS for action.

Repayment

The PHSA makes a Covered Entity liable to the manufacturer for any discount improperly obtained as a result of diversion (dispensing to ineligible patients), duplicate discounts (using 340B drugs for Medicaid patients for whom the state also receives a rebate) or ineligibility of the entity to participate in the 340B Program. This liability also runs to diversion and duplicate discounting that occurs at a Contract Pharmacy. The Guidance instructs Covered Entities and manufacturers to work together regarding repayment (and refunds) within 90 days of identifying a violation (or overcharge). The manufacturer retains discretion regarding whether or not to request repayment based on business considerations, provided the manufacturer complies with applicable law, including the federal anti-kickback statute, in exercising that discretion. Some manufacturers may decide not to accept repayments below a certain minimum threshold amount, or to use a credit/rebill mechanism to handle repayments. Regardless of the manufacturer's process or its decisions regarding repayment, the Covered Entity is responsible for submitting a summary of its corrective actions and repayments to HHS for compliance and audit purposes.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.